Research on prostate cancer biology, detection, and outcomes. Covers genetic clues, DNA damage, diet and survival, and screening awareness.
Researchers developed an AI tool called Unfold AI to accurately estimate prostate tumor volume and identify patients likely to benefit from partial gland cryoablation. This approach shows promise in reducing treatment failures by over 70% and improving patient outcomes.
A Rice University statistician has received a $1 million CPRIT award to advance AI-powered precision medicine for prostate cancer. The project aims to identify lethal forms of prostate cancer earlier and improve treatment selection using AI tools and advanced imaging techniques.
Researchers found that the current standard monitoring time of one-and-a-half to two months following surgery is too short to accurately identify recurrence and inform treatment decisions. Monitoring PSA levels for at least three months can avoid overtreatment and mislabel patients as having recurred.
A new study from Edith Cowan University found that regular exercise significantly improved erectile function in patients with prostate cancer. The research suggests that exercise medicine should be considered a key part of their treatment, and may help address relationship issues caused by sexual dysfunction.
Active surveillance is an extremely safe option for prostate cancer patients, with a 0.1% mortality rate after 10 years. A personalized approach to treatment is necessary, taking into account the patient's age and disease stage.
Researchers found that aspirin prevents cancers from spreading by decreasing a clotting factor called thromboxane A2 and releasing T cells from suppression. This discovery could lead to the development of targeted treatments to prevent cancer metastasis, making aspirin potentially less expensive than antibody-based therapies.
Researchers at University of Arizona Cancer Center found that an immunotherapy previously shown to be ineffective against prostate cancer may have therapeutic potential when combined with a specific protein inhibitor. The study's co-author, Noel Warfel, PhD, identified a way to sensitize prostate tumors to immune checkpoint inhibitors ...
A study uncovered new genetic clues explaining why some prostate cancers grow slowly while others become life-threatening, identifying 223 mutations that determine tumor progression. The research shows germline and somatic variability work together to initiate and drive prostate cancer.
Researchers have developed a new strategy to protect cancer patients from radiation-induced DNA damage using a protein from tardigrades. The approach makes use of messenger RNA encoding the protein, which is delivered to patient tissues before radiation treatment. This reduces double-stranded DNA breaks by 50% in mouse models.
A large-scale study has found huge variation in GP practices on prostate cancer testing, with one in five patients diagnosed without symptoms. The study suggests a need for more consistent approach to testing people without symptoms to redress the imbalance.
A new study by Rice University and Vanderbilt University researchers found that combining focused ultrasound with the existing protein therapy TRAIL can significantly reduce tumor size and burden in prostate cancer models. The therapy works by amplifying the anticancer effects of TRAIL via Piezo1 activation, which triggers cell death.
A study found that pro-inflammatory molecules contribute to benign prostatic hyperplasia (BPH) in aging men, especially those with metabolic syndrome. Men with BPH had higher levels of pro-inflammatory markers and lower anti-inflammatory substances, suggesting a link between inflammation and prostate conditions.
A recent study reveals genes that may help predict prostate cancer outcomes, including androgen receptor AR-V7 and p160 gene family. The research suggests these genes could serve as potential prognostic biomarkers for prostate cancer, highlighting the importance of androgen signaling in disease progression.
A new laparoscopic imaging technique uses stereo depth estimation and speckle-illumination SFDI to accurately map the optical properties of biological tissue. The device provides detailed optical property maps, enabling surgeons to identify critical tumor margins and improve clinical outcomes.
Donald Patrick McDonnell, a professor at Duke University School of Medicine, has been awarded the Endocrine Society's John D. Baxter Prize for his research on hormone therapies for treating breast and prostate cancers. His work led to the discovery of novel treatments for these cancers and has improved patient care.
A new study found that RAD51 testing can complement next-generation sequencing in personalizing prostate cancer treatment, especially for patients with homologous recombination repair-defective tumors. The biomarker showed high sensitivity and specificity for identifying BRCA1/2 alterations.
Researchers at UCSF used CRISPR gene editing technology to transform ordinary white fat cells into 'beige' fat cells that voraciously consume calories to make heat. Implanted near tumors, these cells outcompeted cancer cells for nutrients, beating back five types of cancer in lab experiments.
A new urine test for prostate cancer has been shown to be highly accurate and can be used at home. The test, known as MyProstateScore 2.0 (MPS2), analyzes 18 genes associated with prostate cancer and can rule out clinically significant cancers with high accuracy.
A new study by UC San Francisco found a marked increase in advanced prostate cancer rates across California since doctors stopped routine screening, with death rates plateauing in most regions. The study emphasizes the need for screening that can identify fatal tumors without raising false alarms.
A recent study published in Lancet Oncology reveals a significant link between early side effects from radiation therapy for prostate cancer and long-term complications. Men who experience moderate acute urinary or bowel side effects during treatment are nearly twice as likely to develop late urinary or bowel issues, respectively. This...
The latest therapeutic strategies for castration-resistant prostate cancer focus on innovative proteolysis-targeting chimera (PROTAC) technology, which degrades target proteins and holds potential as effective treatments. PROTAC technology is a novel means to combat resistance mechanisms in PRPC.
Researchers have clinically validated a urine test that can detect aggressive prostate cancer, potentially avoiding unnecessary biopsies and overtreatment. The test, called MyProstateScore 2.0, analyzes 18 genes linked to high-grade prostate cancer and showed a 94% sensitivity rate.
A study of men with a family history of prostate cancer discovered an inherited form of prostate cancer linked to the mutated gene WNT9B. This gene variant increases prostate cancer risk by two- to 12-fold, comparable to breast cancer risk conferred by pathogenic mutations.
A systematic review found that genomic classifier tests can influence risk classifications and treatment decisions for patients with localized prostate cancer, but more research is needed to understand their cost-effectiveness and impact on racial groups. The tests may lead to more conservative management options, such as active survei...
A group of Chinese experts has developed a comprehensive consensus aimed at addressing critical gaps in prostate cancer management. The consensus recommends starting PSA screening at age 50 and endorsing the use of next-generation hormonal agents combined with ADT for high-volume metastatic castration-sensitive prostate cancer patients.
The new NCCN Guidelines for Patients: Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, and Prostate Cancer provide evidence-based recommendations for assessing and testing for inherited genetic mutations. The resource aims to inform individuals about their cancer risks based on personal or family history.
Researchers developed a novel approach using lipid nanoparticles to deliver mRNA and siRNA, restoring tumor suppressors and inhibiting tumor drivers in prostate cancer cells. This technique holds promise for treating various types of cancer by targeting specific pathways related to tumor growth and suppression.
Researchers are investigating a water vapor system that uses small, targeted amounts of steam to kill cancer cells in patients with intermediate-risk prostate cancer. The trial aims to explore the safety and effectiveness of this treatment as an alternative to traditional therapies, which can cause life-altering side effects.
A new study found that nearly half of high-risk prostate cancer patients have metastatic disease when evaluated with advanced PSMA-PET imaging, suggesting traditional imaging may underestimate cancer spread. This challenge the interpretation of previous studies like EMBARK trial, and support the inclusion of PSMA-PET for patient select...
Most study participants struggled to understand standard prostate cancer pathology reports, but found patient-centered reports easier to comprehend. PCPRs reduced perceived worry in low-risk conditions compared to traditional reports, suggesting their inclusion could enhance patient care.
A study by Charité – Universitätsmedizin Berlin found that an MRI-first approach to detecting prostate cancer is safe and reliable, with normal MRI findings indicating a low risk of aggressive cancer. The strategy involves regular urological checks instead of biopsies for patients without suspicious findings.
Researchers discovered a novel vulnerability in prostate cancer cells that starves them of critical nutrients called amino acids. By inhibiting two proteins, GCN2 and p53, the team found a way to effectively destroy prostate tumors.
Researchers discovered a novel platinum complex that targets androgen receptor signaling, inhibiting cell growth and survival in prostate cancer cells. The complex, 5-H-Y, showed stronger cytotoxic effects than cisplatin with minimal toxicity, offering a promising approach to treating advanced prostate cancer.
A new study found that a low omega-6, high omega-3 diet with fish oil supplements significantly reduced prostate cancer cell proliferation in men. The findings suggest that dietary changes could potentially delay or prevent the need for more aggressive treatments.
Researchers at MSU are developing a novel approach to combat prostate cancer using promethium-149, a radioactive isotope that can deliver high doses of radiation directly to cancer cells. The team plans to test the effectiveness of 149Pm against industry-standard 177Lu and explore its potential for treating other types of cancers.
A new DNA sequencing test called AR-ctDETECT has been found to distinguish between patients with poor and favorable prognoses in advanced prostate cancer. The test identified circulating tumor DNA in 59% of patients and showed that detectable ctDNA was associated with worse overall survival.
The study estimated that prevention, screening, and treatment efforts in the US led to an average of 8 out of 10 cancer deaths being avoided for breast, cervical, colorectal, lung, and prostate cancers combined. The total number of averted cancer deaths was approximately 5.94 million between 1975 and 2020.
Researchers have identified UBA1 enzyme as key mediator for immune response to tumors, inhibiting its activity increases T-cell recruitment and lowers tumor resistance. Pairing UBA1 inhibitors with immune checkpoint blockade therapies may make immunotherapy more effective for patients with 'cold' tumors.
Researchers activate glycoprotein 130 and its associated signaling pathway to slow down tumor growth in prostate cancer, stimulating immune system to fight tumour cells. Studies of tissue samples from prostate cancer patients show positive correlation with better survival rates.
Researchers found that immunosuppression in prostate cancer is associated with a specialised epithelial subtype. This interaction between the immune system and club-like epithelial cells can lead to treatment resistance in patients with advanced, treatment-resistant prostate cancer.
A new study by Weill Cornell Medicine scientists reveals that the enzyme EZH2 drives aggressive tumor growth in treatment-resistant prostate cancers. The absence of protein PKCλ/ι enables EZH2's alternative function, promoting cancer progression despite androgen receptor inhibitors.
Between 2010 and 2020, there was a significant rise in the use of active surveillance and watchful waiting for patients with intermediate-risk prostate cancer. This trend corresponds to better long-term results and advancements in imaging and risk stratification.
A new mathematical model of prostate cancer has been developed, revealing key findings on genetic changes and tumour growth. The study shows that strong genetic changes are necessary for aggressive tumours to develop early in the course of tumour development.
A Chinese Medical Journal study reveals that patients with prostate cancer can undergo surgical removal without a pre-operative biopsy, using a combination of mpMRI and PSMA PET/CT imaging. This approach reduces costs and complications associated with traditional biopsy methods.
Patients receiving MRI-guided SBRT experienced significantly fewer urinary and bowel side effects compared to CT-guided treatment. MRI guidance also correlated with improved scores on specific quality-of-life measures, including bowel function and sexual health.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with advanced small cell bladder cancer and small cell/neuroendocrine prostate cancer. The study found that the combination treatment resul...
Researchers have discovered a new strategy to overcome docetaxel resistance in advanced prostate cancer patients, which may improve the efficacy of chemotherapy and prolong overall survival. The approach involves inhibiting cholesterol and lipid biosynthesis, reinducing sensitivity to the drug docetaxel.
A recent study has uncovered a genetic variant in the PSA gene that is associated with aggressive prostate cancer. This finding could lead to the development of a novel point-of-care device that can identify high-risk patients with low blood PSA levels, enabling early detection and treatment.
A new study by Cedars-Sinai reveals that significant percentages of older men with intermediate- and high-risk prostate cancers are being subjected to aggressive treatments that may not extend their lives, highlighting the need for a more personalized approach to cancer treatment. The study suggests that better estimation, communicatio...
A new strategy for treating prostate cancer has been developed by blocking the GP130 signalling pathway, contrary to current medical understanding. The study found that activating GP130 in prostate cells reduces tumour growth and stimulates the immune system to fight cancer cells.
A comprehensive analysis of 52,000 men with prostate cancer treatment found substantial long-term risks of urinary and sexual complications. Men treated with radiotherapy faced a threefold risk of bladder cancer diagnosis, while those who underwent prostatectomy had a sixfold increased risk of complications.
Researchers have identified 22 pesticides consistently linked to prostate cancer incidence across US counties, including 2,4-D. Four pesticides are also associated with increased prostate cancer mortality rates.
Researchers developed an AI model that can identify and measure aggressive prostate cancer lesions with high accuracy. The model's estimates of tumor size were associated with the likelihood of cancer recurrence or metastasis.
A new discovery by Cold Spring Harbor Laboratory's Lloyd Trotman suggests that menadione, a precursor to vitamin K, can slow prostate cancer progression in mice. The supplement depletes a lipid called PI(3)P, killing cancer cells and slowing disease progression significantly.
UTEP researchers developed a portable device that can detect colorectal and prostate cancer quickly and accurately, reducing the need for costly instruments. The device is low-cost, sensitive, and analyzes samples in just an hour.
A new study from the University of Texas at Arlington suggests that analyzing RNA in urine can show changes in cell types, revealing early signs of cancer and other diseases. This method could help clinicians detect problems earlier when they are more easily treated without invasive procedures.
The UCLA Urology department has been awarded $6 million to continue the IMPACT program, providing comprehensive prostate cancer treatment for underinsured and uninsured Californians. The program has helped over 2,300 men receive treatment services since its inception.
A new study suggests that a healthy diet may help keep low-grade prostate cancer from progressing to more aggressive states in men undergoing active surveillance. The research team led by Johns Hopkins Medicine found that a reduced risk of prostate cancer progression is associated with a healthy diet.
Researchers at Duke University Medical Center found that Black men with metastatic prostate cancer have the greatest survival benefit from sipuleucel-T immunotherapy, possibly due to a genetic variant that encourages an inflammatory response. The study could lead to targeted treatment for patients who will benefit most
A groundbreaking study has demonstrated the clinical success of a new nanoparticle-based, laser-guided therapy for prostate cancer treatment. The therapy successfully eliminated cancerous cells in 73% of patients after 12 months while preserving key functions and side effects.